Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The comparative pharmacokinetics of physical manipulation by crushing of Xtampza® ER compared with OxyContin®.

Brennan MJ, Kopecky EA, Marseilles A, O'Connor M, Fleming AB.

Pain Manag. 2017 Nov;7(6):461-472. doi: 10.2217/pmt-2017-0030. Epub 2017 Sep 18.

2.

Author Correction to: In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations.

Mayock SP, Saim S, Fleming AB.

Clin Drug Investig. 2017 Dec;37(12):1203. doi: 10.1007/s40261-017-0599-8.

PMID:
29094281
3.

Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration.

Butler SF, Black RA, Fleming AB.

Pain Med. 2017 Jul 8. doi: 10.1093/pm/pnx151. [Epub ahead of print]

PMID:
29016905
4.

In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations.

Mayock SP, Saim S, Fleming AB.

Clin Drug Investig. 2017 Dec;37(12):1117-1124. doi: 10.1007/s40261-017-0561-9. Erratum in: Clin Drug Investig. 2017 Dec;37(12 ):1203.

5.

Erratum to: Exploring the Interplay between Rescue Drugs, Data Imputation, and Study Outcomes: Conceptual Review and Qualitative Analysis of an Acute Pain Data Set.

Singla NK, Meske DS, Desjardins PJ.

Pain Ther. 2017 Dec;6(2):177-178. doi: 10.1007/s40122-017-0078-1. No abstract available.

6.

Exploring the Interplay between Rescue Drugs, Data Imputation, and Study Outcomes: Conceptual Review and Qualitative Analysis of an Acute Pain Data Set.

Singla NK, Meske DS, Desjardins PJ.

Pain Ther. 2017 Dec;6(2):165-175. doi: 10.1007/s40122-017-0074-5. Epub 2017 Jul 4. Review. Erratum in: Pain Ther. 2017 Aug 29;:.

7.

Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.

Kopecky EA, Vaughn B, Lagasse S, O'Connor M.

Drugs Aging. 2017 Aug;34(8):603-613. doi: 10.1007/s40266-017-0473-7.

8.

Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.

Smith SM, Jones JK, Katz NP, Roland CL, Setnik B, Trudeau JJ, Wright S, Burke LB, Comer SD, Dart RC, Dionne R, Haddox JD, Jaffe JH, Kopecky EA, Martell BA, Montoya ID, Stanton M, Wasan AD, Turk DC, Dworkin RH.

J Pain. 2017 Nov;18(11):1287-1294. doi: 10.1016/j.jpain.2017.03.015. Epub 2017 May 4.

9.

Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).

Kopecky EA, Fleming AB, Levy-Cooperman N, O'Connor M, M Sellers E.

J Clin Pharmacol. 2017 Apr;57(4):500-512. doi: 10.1002/jcph.833. Epub 2016 Nov 1.

10.

Participant Preferences for Pharmacologic Chronic Pain Treatment Trial Characteristics: An ACTTION Adaptive Choice-Based Conjoint Study.

Smith SM, Gewandter JS, Kitt RA, Markman JD, Vaughan JA, Cowan P, Kopecky EA, Malamut R, Sadosky A, Tive L, Turk DC, Dworkin RH.

J Pain. 2016 Nov;17(11):1198-1206. doi: 10.1016/j.jpain.2016.07.008. Epub 2016 Aug 20.

PMID:
27555429
11.

In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres.

Fleming AB, Scungio TA, Grima MP, Mayock SP.

J Opioid Manag. 2016 Jan-Feb;12(1):57-65. doi: 10.5055/jom.2016.0312.

PMID:
26908304
12.
13.

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.

Pain Med. 2015 Nov;16(11):2142-51. doi: 10.1111/pme.12834. Epub 2015 Jun 22.

PMID:
26108255
14.

Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).

Fleming AB, Carlson DR, Varanasi RK, Grima M, Mayock SP, Saim S, Kopecky EA.

Pain Pract. 2016 Mar;16(3):334-44. doi: 10.1111/papr.12280. Epub 2015 Jan 12.

PMID:
25639548
15.

Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.

Kopecky EA, Fleming AB, Noonan PK, Varanasi RK, Grima M, Saim S, Mayock SP.

J Opioid Manag. 2014 Jul-Aug;10(4):233-46. doi: 10.5055/jom.2014.0211.

PMID:
25162603
16.

Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam.

Trumbore MW, Goldstein JA, Gurge RM.

J Drugs Dermatol. 2009 Mar;8(3):299-304.

PMID:
19271381

Supplemental Content

Loading ...
Support Center